Clinical and pathological impact of an optimal assessment of brain invasion for grade 2 meningioma diagnosis: lessons from a series of 291 cases.

2021 WHO classification of tumors of the central nervous system Brain invasion Grade 2 meningioma Onco-functional outcome Survival analysis

Journal

Neurosurgical review
ISSN: 1437-2320
Titre abrégé: Neurosurg Rev
Pays: Germany
ID NLM: 7908181

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 10 01 2022
accepted: 15 04 2022
revised: 07 04 2022
pubmed: 30 4 2022
medline: 6 8 2022
entrez: 29 4 2022
Statut: ppublish

Résumé

Brain invasion has not been recognized as a standalone criterion for atypical meningioma by the WHO classification until 2016. Since the 2007 edition suggested that meningiomas harboring brain invasion could be classified as grade 2, brain invasion study was progressively strengthened in our center, based on a strong collaboration between neurosurgeons and neuropathologists regarding sample orientation and examination. Practice changes were considered homogeneous enough in 2011. The aim of the present study was to evaluate the impact of gross practice change on the clinical and pathological characteristics of intracranial meningiomas classified as grade 2.The characteristics of consecutive patients with a grade 2 meningioma surgically managed before (1998-2005, n = 125, group A) and after (2011-2014, n = 166, group B) practices changed were retrospectively reviewed.Sociodemographical and clinical parameters were comparable in groups A and B, and the median age was 62 years in both groups (p = 0.18). The 5-year recurrence rates (23.2% vs 29.5%, p = 0.23) were similar. In group A, brain invasion was present in 48/125 (38.4%) cases and was more frequent than in group B (14/166, 8.4%, p < 0.001). In group A, 33 (26.4%) meningiomas were classified as grade 2 solely based on brain invasion (group A

Identifiants

pubmed: 35488071
doi: 10.1007/s10143-022-01792-6
pii: 10.1007/s10143-022-01792-6
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2797-2809

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Adeli A, Hess K, Mawrin C, Streckert EMS, Stummer W, Paulus W, Kemmling A, Holling M, Heindel W, Schmidt R, Spille DC, Sporns PB, Brokinkel B (2018) Prediction of brain invasion in patients with meningiomas using preoperative magnetic resonance imaging. Oncotarget 9:35974–35982. https://doi.org/10.18632/oncotarget.26313
doi: 10.18632/oncotarget.26313 pubmed: 30542511 pmcid: 6267603
Aghi MK, Carter BS, Cosgrove GR, Ojemann RG, Amin-Hanjani S, Martuza RL, Curry WT, Barker FG (2009) Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 64:56–60. https://doi.org/10.1227/01.NEU.0000330399.55586.63 (discussion 60)
doi: 10.1227/01.NEU.0000330399.55586.63 pubmed: 19145156
Backer-Grøndahl T, Moen BH, Arnli MB, Torseth K, Torp SH (2014) Immunohistochemical characterization of brain-invasive meningiomas. Int J Clin Exp Pathol 7:7206–7219
pubmed: 25400818 pmcid: 4230100
Barresi V, Lionti S, Caliri S, Caffo M (2018) Histopathological features to define atypical meningioma: What does really matter for prognosis? Brain Tumor Pathol 35:168–180. https://doi.org/10.1007/s10014-018-0318-z
doi: 10.1007/s10014-018-0318-z pubmed: 29671247
Baumgarten P, Gessler F, Schittenhelm J, Skardelly M, Tews DS, Senft C, Dunst M, Imoehl L, Plate KH, Wagner M, Steinbach JP, Seifert V, Mittelbronn M, Harter PN (2016) Brain invasion in otherwise benign meningiomas does not predict tumor recurrence. Acta Neuropathol 132:479–481. https://doi.org/10.1007/s00401-016-1598-1
doi: 10.1007/s00401-016-1598-1 pubmed: 27464983
Bi WL, Zhang M, Wu WW, Mei Y, Dunn IF (2016) Meningioma genomics: diagnostic, prognostic, and therapeutic applications. Front Surg 3:40. https://doi.org/10.3389/fsurg.2016.00040
doi: 10.3389/fsurg.2016.00040 pubmed: 27458586 pmcid: 4933705
Biczok A, Jungk C, Egensperger R, von Deimling A, Suchorska B, Tonn JC, Herold-Mende C, Schichor C (2019) Microscopic brain invasion in meningiomas previously classified as WHO grade I is not associated with patient outcome. J Neurooncol 145:469–477. https://doi.org/10.1007/s11060-019-03312-x
doi: 10.1007/s11060-019-03312-x pubmed: 31713016
Brokinkel B, Hess K, Mawrin C (2017) Brain invasion in meningiomas-clinical considerations and impact of neuropathological evaluation: a systematic review. Neuro Oncol 19:1298–1307. https://doi.org/10.1093/neuonc/nox071
doi: 10.1093/neuonc/nox071 pubmed: 28419308 pmcid: 5596167
Brokinkel B, Stummer W (2016) Brain invasion in meningiomas: the rising importance of a uniform neuropathologic assessment after the release of the 2016 World Health Organization classification of central nervous system tumors. World Neurosurg 95:614–615. https://doi.org/10.1016/j.wneu.2016.08.047
doi: 10.1016/j.wneu.2016.08.047 pubmed: 27923471
Budohoski KP, Clerkin J, Millward CP, O’Halloran PJ, Waqar M, Looby S, Young AMH, Guilfoyle MR, Fitzroll D, Devadass A, Allinson K, Farrell M, Javadpour M, Jenkinson MD, Santarius T, Kirollos RW (2018) Predictors of early progression of surgically treated atypical meningiomas. Acta Neurochir (Wien) 160:1813–1822. https://doi.org/10.1007/s00701-018-3593-x
doi: 10.1007/s00701-018-3593-x
Bulleid LS, James Z, Lammie A, Hayhurst C, Leach PA (2019) The effect of the revised WHO classification on the incidence of grade II meningioma. Br J Neurosurg 1–3. https://doi.org/10.1080/02688697.2019.1639616
Champeaux C, Houston D, Dunn L (2017) Atypical meningioma. A study on recurrence and disease-specific survival. Neurochirurgie 63:273–281. https://doi.org/10.1016/j.neuchi.2017.03.004
doi: 10.1016/j.neuchi.2017.03.004 pubmed: 28882609
Chen WC, Magill ST, Wu A, Vasudevan HN, Morin O, Aghi MK, Theodosopoulos PV, Perry A, McDermott MW, Sneed PK, Braunstein SE, Raleigh DR (2018) Histopathological features predictive of local control of atypical meningioma after surgery and adjuvant radiotherapy. J Neurosurg 1–8. https://doi.org/10.3171/2017.9.JNS171609
Cornelius JF, Slotty PJ, Steiger HJ, Hanggi D, Polivka M, George B (2013) Malignant potential of skull base versus non-skull base meningiomas: clinical series of 1,663 cases. Acta Neurochir 155:407–413
doi: 10.1007/s00701-012-1611-y
Durand A, Labrousse F, Jouvet A, Bauchet L, Kalamaridès M, Menei P, Deruty R, Moreau JJ, Fèvre-Montange M, Guyotat J (2009) WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol 95:367–375. https://doi.org/10.1007/s11060-009-9934-0
doi: 10.1007/s11060-009-9934-0 pubmed: 19562258
Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, von Deimling A, Stavrinou P, Lefranc F, Lund-Johansen M, Moyal EC-J, Brandsma D, Henriksson R, Soffietti R, Weller M (2016) EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 17:e383-391. https://doi.org/10.1016/S1470-2045(16)30321-7
doi: 10.1016/S1470-2045(16)30321-7 pubmed: 27599143
Gousias K, Schramm J, Simon M (2016) The Simpson grading revisited: aggressive surgery and its place in modern meningioma management. J Neurosurg 125:551–560. https://doi.org/10.3171/2015.9.JNS15754
doi: 10.3171/2015.9.JNS15754 pubmed: 26824369
Hess K, Spille DC, Adeli A, Sporns PB, Brokinkel C, Grauer O, Mawrin C, Stummer W, Paulus W, Brokinkel B (2018) Brain invasion and the risk of seizures in patients with meningioma. J Neurosurg 1–8. https://doi.org/10.3171/2017.11.JNS172265
Jääskeläinen J (1986) Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis Surg Neurol 26:461–469. https://doi.org/10.1016/0090-3019(86)90259-4
doi: 10.1016/0090-3019(86)90259-4 pubmed: 3764651
Jenkinson MD, Santarius T, Zadeh G, Aldape KD (2017) Atypical meningioma-is it time to standardize surgical sampling techniques? Neuro Oncol 19:453–454. https://doi.org/10.1093/neuonc/now245
doi: 10.1093/neuonc/now245 pubmed: 28391316
Kim D, Niemierko A, Hwang WL, Stemmer-Rachamimov AO, Curry WT, Barker FG, Martuza RL, Oh KS, Loeffler JS, Shih HA (2018) Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas. J Neurosurg 128:1123–1132. https://doi.org/10.3171/2016.11.JNS16913
doi: 10.3171/2016.11.JNS16913 pubmed: 28621619
Klinger DR, Flores BC, Lewis JJ, Hatanpaa K, Choe K, Mickey B, Barnett S (2015) Atypical meningiomas: recurrence, reoperation, and radiotherapy. World Neurosurg 84:839–845. https://doi.org/10.1016/j.wneu.2015.04.033
doi: 10.1016/j.wneu.2015.04.033 pubmed: 25916182
Liu Y, Chotai S, Chen M, Jin S, Qi S, Pan J (2015) Preoperative radiologic classification of convexity meningioma to predict the survival and aggressive meningioma behavior. PLoS ONE 10:e0118908. https://doi.org/10.1371/journal.pone.0118908
doi: 10.1371/journal.pone.0118908 pubmed: 25786236 pmcid: 4364713
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109. https://doi.org/10.1007/s00401-007-0243-4
doi: 10.1007/s00401-007-0243-4 pubmed: 17618441 pmcid: 1929165
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1
doi: 10.1007/s00401-016-1545-1 pubmed: 27157931
Maiuri F, Mariniello G, Guadagno E, Barbato M, Corvino S, Caro DBD, M, (2019) WHO grade, proliferation index, and progesterone receptor expression are different according to the location of meningioma. Acta Neurochir (Wien) 161:2553–2561. https://doi.org/10.1007/s00701-019-04084-z
doi: 10.1007/s00701-019-04084-z
Mantle RE, Lach B, Delgado MR, Baeesa S, Bélanger G (1999) Predicting the probability of meningioma recurrence based on the quantity of peritumoral brain edema on computerized tomography scanning. J Neurosurg 91:375–383. https://doi.org/10.3171/jns.1999.91.3.0375
doi: 10.3171/jns.1999.91.3.0375 pubmed: 10470810
Palma L, Celli P, Franco C, Cervoni L, Cantore G (1997) Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases. J Neurosurg 86:793–800. https://doi.org/10.3171/jns.1997.86.5.0793
doi: 10.3171/jns.1997.86.5.0793 pubmed: 9126894
Park J, Sade B, Oya S, Kim C, Lee J (2014) The influence of age on the histological grading of meningiomas. Neurosurg Rev 37:425–429
doi: 10.1007/s10143-014-0537-7
Perry A (2021) The definition and role of brain invasion in meningioma grading: still controversial after all these years. Free Neuropathology 2:8–8. https://doi.org/10.17879/freeneuropathology-2021-3276
doi: 10.17879/freeneuropathology-2021-3276
Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC (1999) “Malignancy” in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 85:2046–2056. https://doi.org/10.1002/(sici)1097-0142(19990501)85:9%3c2046::aid-cncr23%3e3.0.co;2-m
doi: 10.1002/(sici)1097-0142(19990501)85:9<2046::aid-cncr23>3.0.co;2-m pubmed: 10223247
Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM (1997) Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol 21:1455–1465. https://doi.org/10.1097/00000478-199712000-00008
doi: 10.1097/00000478-199712000-00008 pubmed: 9414189
Pizem J, Velnar T, Prestor B, Mlakar J, Popovic M (2014) Brain invasion assessability in meningiomas is related to meningioma size and grade, and can be improved by extensive sampling of the surgically removed meningioma specimen. Clin Neuropathol 33:354–363. https://doi.org/10.5414/NP300750
doi: 10.5414/NP300750 pubmed: 25034703
Ressel A, Fichte S, Brodhun M, Rosahl SK, Gerlach R (2019) WHO grade of intracranial meningiomas differs with respect to patient’s age, location, tumor size and peritumoral edema. J Neurooncol 145:277–286. https://doi.org/10.1007/s11060-019-03293-x
doi: 10.1007/s11060-019-03293-x pubmed: 31578671
Sade B, Chahlavi A, Krishnaney A, Nagel S, Choi E, Lee JH (2007) World Health Organization grades II and iii meningiomas are rare in the cranial base and spine. Neurosurgery 61:1194–1198. https://doi.org/10.1227/01.neu.0000306097.38141.65 (discussion 1198)
doi: 10.1227/01.neu.0000306097.38141.65 pubmed: 18162898
Salah F, Tabbarah A, ALArab Y N, Asmar K, Tamim H, Makki M, Sibahi A, Hourani R, (2019) Can CT and MRI features differentiate benign from malignant meningiomas? Clin Radiol 74:898.e15-898.e23. https://doi.org/10.1016/j.crad.2019.07.020
doi: 10.1016/j.crad.2019.07.020
Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20:22–39
doi: 10.1136/jnnp.20.1.22
Spille DC, Heß K, Sauerland C, Sanai N, Stummer W, Paulus W, Brokinkel B (2016) Brain invasion in meningiomas: incidence and correlations with clinical variables and prognosis. World Neurosurg 93:346–354. https://doi.org/10.1016/j.wneu.2016.06.055
doi: 10.1016/j.wneu.2016.06.055 pubmed: 27344043
Sun SQ, Kim AH, Cai C, Murphy RKJ, DeWees T, Sylvester P, Dacey RG, Grubb RL, Rich KM, Zipfel GJ, Dowling JL, Leuthardt EC, Leonard JR, Evans J, Simpson JR, Robinson CG, Perrin RJ, Huang J, Chicoine MR (2014) Management of atypical cranial meningiomas, part 1: predictors of recurrence and the role of adjuvant radiation after gross total resection. Neurosurgery 75:347–354. https://doi.org/10.1227/NEU.0000000000000461 (discussion 354–355; quiz 355)
doi: 10.1227/NEU.0000000000000461 pubmed: 24932707
Timme M, Thomas C, Spille DC, Stummer W, Ebel H, Ewelt C, Hans F-J, Schick U, Puchner M, Wildförster U, Bruns B, Trost HA, Holling M, Grauer O, Hess K, Brokinkel B (2019) Brain invasion in meningiomas: does surgical sampling impact specimen characteristics and histology? Neurosurg Rev. https://doi.org/10.1007/s10143-019-01125-0
doi: 10.1007/s10143-019-01125-0 pubmed: 31161444
Vranic A, Popovic M, Cör A, Prestor B, Pizem J (2010) Mitotic count, brain invasion, and location are independent predictors of recurrence-free survival in primary atypical and malignant meningiomas: a study of 86 patients. Neurosurgery 67:1124–1132. https://doi.org/10.1227/NEU.0b013e3181eb95b7
doi: 10.1227/NEU.0b013e3181eb95b7 pubmed: 20881577
Yang S-Y, Park C-K, Park S-H, Kim DG, Chung YS, Jung H-W (2008) Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry 79:574–580. https://doi.org/10.1136/jnnp.2007.121582
doi: 10.1136/jnnp.2007.121582 pubmed: 17766430
Yoon H, Mehta MP, Perumal K, Helenowski IB, Chappell RJ, Akture E, Lin Y, Marymont MAH, Sejpal S, Parsa A, Chandler JR, Bendok BR, Rosenow J, Salamat S, Kumthekar P, Raizer JK, Baskaya MK (2015) Atypical meningioma: randomized trials are required to resolve contradictory retrospective results regarding the role of adjuvant radiotherapy. J Cancer Res Ther 11:59–66. https://doi.org/10.4103/0973-1482.148708
doi: 10.4103/0973-1482.148708 pubmed: 25879338
Yun S, Koh JM, Lee KS, Seo AN, Nam KH, Choe G (2015) Expression of c-MET in invasive meningioma. J Pathol Transl Med 49:44–51. https://doi.org/10.4132/jptm.2014.10.13
doi: 10.4132/jptm.2014.10.13 pubmed: 25812657 pmcid: 4357404
Zaher A, Abdelbari Mattar M, Zayed DH, Ellatif RA, Ashamallah SA (2013) Atypical meningioma: a study of prognostic factors. World Neurosurg 80:549–553. https://doi.org/10.1016/j.wneu.2013.07.001
doi: 10.1016/j.wneu.2013.07.001 pubmed: 23871812

Auteurs

Thiébaud Picart (T)

Department of Neurosurgery, Hôpital Neurologique Pierre Wertheimer, 59 Boulevard Pinel, 69667, Hospices Civils de Lyon, Bron, France. thiebaud.picart@chu-lyon.fr.
Claude Bernard University, Lyon 1, Lyon, France. thiebaud.picart@chu-lyon.fr.
Department of Cancer Cell Plasticity - INSERM U1052, Cancer Research Center of Lyon, Lyon, France. thiebaud.picart@chu-lyon.fr.

Chloé Dumot (C)

Department of Neurosurgery, Hôpital Neurologique Pierre Wertheimer, 59 Boulevard Pinel, 69667, Hospices Civils de Lyon, Bron, France.
Claude Bernard University, Lyon 1, Lyon, France.
CarMeN Laboratory, Inserm U1060, INRA U1397, INSA Lyon, Université Claude Bernard, Lyon 1, Lyon, France.

Jacques Guyotat (J)

Department of Neurosurgery, Hôpital Neurologique Pierre Wertheimer, 59 Boulevard Pinel, 69667, Hospices Civils de Lyon, Bron, France.

Vladislav Pavlov (V)

Department of Neurosurgery, Hôpital Neurologique Pierre Wertheimer, 59 Boulevard Pinel, 69667, Hospices Civils de Lyon, Bron, France.

Nathalie Streichenberger (N)

Claude Bernard University, Lyon 1, Lyon, France.
Department of Neuropathology, Groupe Hospitalier Est, Hospices Civils de Lyon, Bron, France.
CNRS UMR 5310 - INSERM U1217, Institut NeuroMyogène, Lyon, France.

Alexandre Vasiljevic (A)

Claude Bernard University, Lyon 1, Lyon, France.
Department of Neuropathology, Groupe Hospitalier Est, Hospices Civils de Lyon, Bron, France.

Tanguy Fenouil (T)

Claude Bernard University, Lyon 1, Lyon, France.
Department of Neuropathology, Groupe Hospitalier Est, Hospices Civils de Lyon, Bron, France.

Anne Durand (A)

Department of Neurosurgery, Medipole Lyon Villeurbanne MHP, Villeurbanne, France.

Emmanuel Jouanneau (E)

Department of Neurosurgery, Hôpital Neurologique Pierre Wertheimer, 59 Boulevard Pinel, 69667, Hospices Civils de Lyon, Bron, France.
Claude Bernard University, Lyon 1, Lyon, France.
CNRS UMR5286, Inserm U1052, Cancer Research Center of Lyon, Lyon, France.

François Ducray (F)

Claude Bernard University, Lyon 1, Lyon, France.
Department of Cancer Cell Plasticity - INSERM U1052, Cancer Research Center of Lyon, Lyon, France.
Department of Neurooncology, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France.

Timothée Jacquesson (T)

Department of Neurosurgery, Hôpital Neurologique Pierre Wertheimer, 59 Boulevard Pinel, 69667, Hospices Civils de Lyon, Bron, France.
Claude Bernard University, Lyon 1, Lyon, France.
Laboratory of Anatomy, Faculty of Medicine Lyon Est, University Claude Bernard Lyon 1, Lyon, France.

Moncef Berhouma (M)

Department of Neurosurgery, Hôpital Neurologique Pierre Wertheimer, 59 Boulevard Pinel, 69667, Hospices Civils de Lyon, Bron, France.
Claude Bernard University, Lyon 1, Lyon, France.
CREATIS Laboratory, Inserm U1206, UMR 5220, Université de Lyon, Villeurbanne, France.

David Meyronet (D)

Claude Bernard University, Lyon 1, Lyon, France.
Department of Cancer Cell Plasticity - INSERM U1052, Cancer Research Center of Lyon, Lyon, France.
Department of Neuropathology, Groupe Hospitalier Est, Hospices Civils de Lyon, Bron, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH